Indena confirms its continuous improvement in the supply chain of Escin and Horse Chestnut derivatives, acknowledging the successful completion of the registration of ESCIN (INCI: ESCIN; EC # 229-880-6, CAS # 6805-41-0, Registration 01-2120757334-53-0000) in accordance with the REACH regulation (EC) No 1907/2006 as lead registrant. 

So far Indena is the only company which has completed the full registration, following the pre-registration stage which ended in 2018. As such, the company has generated the relevant data including the complex chemical characterization, fully developed the technical dossier and successfully managed the submission of the registration dossier to ECHA. 

“Escin and Horse Chestnut derivatives are of strategic importance in the realm of botanical active ingredients, being used in some of the best-selling products both in the Pharmaceutical and Personal Care markets. The full characterization presented at ECHA uniquely describes our product - said Elena Uberti for Indena REACH Project. 

The Horse Chestnut derivatives market is not a commodity-like arena, due to the necessary high-quality standards and analytical complexity of its products. With this registration, Indena reconfirms its global leadership in the segment, able 

Indena is the leading company dedicated to the identification, development and production of high quality active principles derived from plants, for use in the pharmaceutical and health food industries. Backed up by almost a century of botanical experience, the company holds more than 100 primary patents, has published more than 1000 scientific studies and co-operates with the world’s most prestigious universities and private research institutions. Indena employs about 800 staff, investing a significant amount of its annual turnover in research, making this activity the key to its success. Headquartered in Milan, Indena has 4 production sites and 5 international branches throughout the world and manages sales in more than 80 countries. The Company's experts communicate and interact constantly with the major international regulatory authorities and cooperate on the update of all the main pharmacopoeias. Today, for the pharma business, Indena has further expanded its CDMO offer encompassing new services. In particular, a kilolab to handle semisynthetic and total synthetic APIs that require high containment (OEL of 20 ng/m3), a new multipurpose GMP pilot plant, a multipurpose fermentation suite and large-and-mid size spray dryers working with organic solvents. 

Back to top

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.